Close Menu
  • About
  • Products
    • Find Solutions
    • Technical Q&A
    • Novelty Search
    • Feasibility Analysis Assistant
    • Material Scout
    • Pharma Insights Advisor
    • More AI Agents For Innovation
  • IP
  • Machinery
  • Material
  • Life Science
Facebook YouTube LinkedIn
Eureka BlogEureka Blog
  • About
  • Products
    • Find Solutions
    • Technical Q&A
    • Novelty Search
    • Feasibility Analysis Assistant
    • Material Scout
    • Pharma Insights Advisor
    • More AI Agents For Innovation
  • IP
  • Machinery
  • Material
  • Life Science
Facebook YouTube LinkedIn
Patsnap eureka →
Eureka BlogEureka Blog
Patsnap eureka →
Home»Life Science»Antibody-Drug Conjugate (ADC) — Global Competitive Landscape Report 2026 | ASCO 2026

Antibody-Drug Conjugate (ADC) — Global Competitive Landscape Report 2026 | ASCO 2026

June 10, 202614 Mins Read
Share
Facebook Twitter LinkedIn Email

ADCs were the dominant targeted therapy class in ASCO 2026, with the number of oral presentations increasing from 6.5% in 2024 to 11.2% in 2026. Over half of these presentations featured registrational Phase III data, with domestic Chinese ADC candidates accounting for 45% of global clinical development, making ADCs the leading area of innovation for domestic Chinese pharmaceutical companies.

This antibody-drug conjugate competitive landscape analysis was built with AI-powered workflows in Eureka LS. The platform fuses patents, literature, and molecular data into a structured report in minutes.

Executive Summary

The antibody-drug conjugate competitive landscape has become one of the most contested fields in oncology. As of June 2026, the Patsnap Eureka pharma-intelligence stack returns 2,868 antibody-drug conjugate (ADC) drug records. It also surfaces 1,293 ADC-tagged patents filed since January 2023 and 1,519 ongoing Phase 2/3 trials globally. Approvals span 20 marketed assets across HER2, Trop-2, Nectin-4, BCMA, FOLR1, CD19, CD22, CD30, CD33, CD79b, c-Met, CD123, and tissue factor. Furthermore, the past 24 months brought five new launches, including Trastuzumab Rezetecan (Hengrui), Telisotuzumab Vedotin (AbbVie), Datopotamab Deruxtecan (Daiichi/AstraZeneca), Sacituzumab Tirumotecan (Kelun/Merck), and Pivekimab Sunirine (AbbVie). Meanwhile, the field saw the largest oncology M&A of the decade — Pfizer’s $43B acquisition of Seagen (closed December 2023) — alongside AbbVie’s $10.1B ImmunoGen buyout (closed February 2024). Together, Daiichi Sankyo, AstraZeneca, AbbVie, Pfizer, Roche, Merck, Gilead, GSK, Hengrui, and Kelun drive most of the approved revenue.


Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated—from extracting molecules to mapping competitive pipelines—into a structured output like the report below.

Arena Overview

Pipeline by Payload Class

ADC pipeline by payload (2,868 total records) — Three payload classes dominate the antibody-drug conjugate competitive landscape. First, topoisomerase I inhibitors (DXd, T030, exatecan derivatives) anchor the modern wave. Notable assets include Trastuzumab Deruxtecan, Datopotamab Deruxtecan, Sacituzumab Govitecan, Sacituzumab Tirumotecan, and Trastuzumab Rezetecan. Second, microtubule inhibitors (MMAE, MMAF, DM1, DM4, soravtansine) anchor first-generation chemistry. Approved examples include Brentuximab Vedotin, Enfortumab Vedotin, Polatuzumab Vedotin, Tisotumab Vedotin, T-DM1, Disitamab Vedotin, Belantamab Mafodotin, and Mirvetuximab Soravtansine. Third, DNA-damaging payloads (calicheamicin, PBD, tesirine) cover hematologic ADCs such as Gemtuzumab Ozogamicin, Inotuzumab Ozogamicin, and Loncastuximab Tesirine.

Patent Activity and Geographic Split

ADC patent activity (2023–2026) — 1,293 ADC-tagged patents have been filed since January 2023. GeneQuantum (Suzhou) leads the 150-patent sample with 6 filings. Kelun Biotech follows with 5 filings, Gilead has 5, Duality Biologics has 4, Seagen has 4, and Cidara has 4. Synaffix, Sutro Biopharma, Zymeworks, Hangzhou Huadong, and Hengrui round out the top 12. As a result, Chinese assignees account for roughly 35% of the 150-patent sample. Meanwhile, US and Japanese originators still dominate the approved-product roster.

Player Summary Table — Tier 1 & Tier 2

PlayerRegionTierPrimary RouteKey Evidence
Daiichi Sankyo / AstraZenecaJP/UKT1 (Leader)DXd topoisomerase I ADCTrastuzumab Deruxtecan (2019), Datopotamab Deruxtecan (2024-12), Ifinatamab Deruxtecan (B7-H3, pipeline); 3 of 150 sampled 2023+ patents
Pfizer (ex-Seagen)UST1 (Leader)MMAE microtubule ADCBrentuximab Vedotin (2011), Enfortumab Vedotin (2019), Tisotumab Vedotin (2021), Inotuzumab Ozogamicin (2017); $43B Seagen acquisition closed Dec 2023
AbbVie (ex-ImmunoGen)UST1 (Leader)Maytansinoid + auristatin ADCMirvetuximab Soravtansine (2022), Telisotuzumab Vedotin (2025-05), Pivekimab Sunirine (2026-05); $10.1B ImmunoGen acquisition closed Feb 2024
Roche / GenentechCH/UST1 (Leader)Maytansinoid + MMAE ADCT-DM1 (2013), Polatuzumab Vedotin (2019)
Merck (MSD)UST1 (Leader)Trop-2 / HER3 ADC partnershipsSacituzumab Tirumotecan (2024-11) Kelun co-development; Patritumab Deruxtecan partnership with Daiichi
Gilead SciencesUST1 (Leader)Trop-2 ADCSacituzumab Govitecan (2020); 5 of 150 sampled 2023+ patents
Astellas PharmaJPT1 (Leader)Nectin-4 MMAE ADCEnfortumab Vedotin co-developed with Seagen/Pfizer; bladder-cancer franchise leader
GSKUKT2 (Challenger)BCMA MMAF ADCBelantamab Mafodotin (2020); 2024 DREAMM-7 readout drove relisting
Jiangsu Hengrui PharmaCNT2 (Challenger)HER2 / TROP2 / B7-H3 / Nectin-4 ADCsTrastuzumab Rezetecan (2025-05); 3 of 150 sampled 2023+ patents
Sichuan Kelun-Botai (Kelun Biotech)CNT2 (Challenger)Trop-2 / HER2 ADCSacituzumab Tirumotecan (Merck partnership), Trastuzumab Botidotin (2025-10); 5 of 150 sampled 2023+ patents
RemeGenCNT2 (Challenger)HER2 MMAE ADCDisitamab Vedotin (2021) HER2-low gastric/urothelial; Seagen ex-Asia license
ADC TherapeuticsCHT2 (Challenger)PBD-dimer ADCLoncastuximab Tesirine (2021) for B-cell lymphoma; pure-play PBD-payload company

Player Summary Table — Tier 3 & Watchlist

PlayerRegionTierPrimary RouteKey Evidence
Duality BiologicsCNT3 (Follower)HER2 / Trop-2 / B7-H3 ADCsBNT323 (BioNTech partnership), DB-1303; 4 of 150 sampled 2023+ patents
GeneQuantum HealthcareCNT3 (Follower)iLDC ADC platform6 of 150 sampled 2023+ patents — highest filing-count platform biotech
SynaffixNLT3 (Follower)GlycoConnect site-specific conjugationAcquired by Lonza 2023; powering multiple licensee programs
Lepu Biopharma / MiracogenCNWatchlistEGFR MMAE ADCBecotatug Vedotin (2025-10) — first EGFR ADC approved globally
LegoChem Biosciences (Ligachem)KRWatchlistConjugation linker platform2 of 150 sampled 2023+ patents; Janssen-licensed Trop-2 ADC LCB-84

Generate Competitive Landscape Reports Like This — in Minutes

Powered by Eureka LS AI

  • ✔ Analyze patents, literature, and pipelines together
  • ✔ Extract molecule & SAR data automatically
  • ✔ Compare competitors and identify key assets
  • ✔ Get structured reports instantly
Start Free (Basic Plan)

Route Differentiation Analysis

Five primary technology routes define the current ADC competitive landscape. Importantly, strength levels are evidence-backed by approved labels, clinical-stage data, and patent activity.

Route × Player Matrix

PlayerTopo I (DXd / SN-38)Microtubule (MMAE/MMAF/DM1)DNA-damaging (PBD/calicheamicin)Site-specific platformBispecific / dual-payload ADC
Daiichi Sankyo / AstraZenecaStrong — T-DXd, Dato-DXd, I-DXdAbsentAbsentModerate — DXd linkerEmerging — pipeline filings
Pfizer (ex-Seagen)AbsentStrong — Brentuximab, Enfortumab, Tisotumab VedotinModerate — Inotuzumab OzogamicinModerate — vc-MMAE chemistryEmerging — multispecific filings
AbbVie (ex-ImmunoGen)AbsentStrong — Mirvetuximab, Telisotuzumab VedotinEmerging — Pivekimab Sunirine PBD-IGNStrong — IGN linker, sulfo-SPDBAbsent
Roche / GenentechAbsentStrong — T-DM1, Polatuzumab VedotinAbsentModerate — internal scaffoldsAbsent
Merck (MSD)Strong — Sacituzumab Tirumotecan, Patritumab DeruxtecanAbsentAbsentAbsentAbsent
GileadStrong — Sacituzumab GovitecanAbsentAbsentAbsentEmerging — Trop-2 next-gen
GSKAbsentStrong — Belantamab Mafodotin (MMAF)AbsentAbsentAbsent
AstellasAbsentStrong — Enfortumab Vedotin (with Seagen)AbsentAbsentAbsent
HengruiStrong — Trastuzumab RezetecanEmerging — Nectin-4 ADCAbsentAbsentEmerging — bispecific ADC filings
Kelun-BotaiStrong — SKB264 (Sacituzumab Tirumotecan)Emerging — HER2 vedotinAbsentAbsentAbsent
RemeGenAbsentStrong — Disitamab VedotinAbsentAbsentAbsent
ADC TherapeuticsAbsentAbsentStrong — Loncastuximab Tesirine PBDAbsentAbsent
Duality BiologicsModerate — DB-1303 HER2 Topo IAbsentAbsentAbsentEmerging — DB-1311 B7-H3
GeneQuantumEmerging — iLDC platformAbsentAbsentStrong — site-specific iLDCEmerging
Synaffix / LonzaAbsentAbsentAbsentStrong — GlycoConnectAbsent

Route concentration observations:

Concentration Takeaways

  • Topoisomerase I (DXd) ADCs are the dominant payload class of the current generation. Specifically, Daiichi Sankyo’s DXd platform anchors three approved assets (T-DXd, Dato-DXd, and the Patritumab/Ifinatamab pipeline). Meanwhile, Merck-Kelun’s Sacituzumab Tirumotecan and Hengrui’s Trastuzumab Rezetecan have validated the route in China-led launches. As a result, DXd-class chemistry now sets the efficacy benchmark in HER2-low breast cancer, Trop-2 NSCLC, and HER3 NSCLC.
  • Microtubule-payload ADCs (MMAE, MMAF, DM1, soravtansine) cover the broadest installed base. Pfizer-Seagen, AbbVie-ImmunoGen, Astellas, RemeGen, and Roche all anchor microtubule franchises. However, real-world data continues to show ocular and hematologic toxicity, which has narrowed indication expansion.
  • DNA-damaging ADCs (PBD, calicheamicin) remain hematology-focused. Pfizer’s Inotuzumab Ozogamicin and ADC Therapeutics’ Loncastuximab Tesirine cover B-cell malignancies. Notably, AbbVie’s Pivekimab Sunirine (CD123-PBD) reached approval on 2026-05-27 for blastic plasmacytoid dendritic cell neoplasm and AML.
  • Site-specific conjugation platforms form the deepest moat for next-generation ADCs. GeneQuantum (iLDC), Synaffix (GlycoConnect, acquired by Lonza in 2023), Sutro Biopharma (XpressCF), and LegoChem all license their conjugation chemistry to multiple programs. Therefore, downstream royalty economics could compound across pipelines.
  • Bispecific and dual-payload ADCs are emerging. For example, BiTE-style HER2×CD3 ADCs and HER2-EGFR dual ADCs appear in 2024–2025 patent filings from Daiichi Sankyo, Hengrui, and Pfizer. Yet none have reached pivotal trials, so this route remains preclinical-to-early-clinical.

Top Player Deep Dives

1. Daiichi Sankyo / AstraZeneca (Tier 1 — Leader)

Primary route: DXd topoisomerase I ADC franchise. Key approved products: Trastuzumab Deruxtecan (Enhertu, 2019-12) for HER2+ and HER2-low breast cancer, gastric cancer, and HER2-mutant NSCLC. Datopotamab Deruxtecan (Datroway, 2024-12) for HR+/HER2− breast cancer. Pipeline: Patritumab Deruxtecan (HER3-DXd) for EGFR-mutant NSCLC. Ifinatamab Deruxtecan (B7-H3-DXd) for small cell lung cancer. Differentiation: The DXd payload combines a high drug-antibody ratio with a stable maleimide-tetrapeptide linker. As a result, T-DXd has redefined HER2-low breast cancer treatment. Trajectory: Daiichi Sankyo plus AstraZeneca now hold three approved DXd ADCs and at least four pivotal-stage candidates. Key risk: Interstitial lung disease (ILD) signal across the DXd class continues to demand mitigation strategies.

Daiichi Sankyo / AstraZeneca DXd franchise comparison:

ProductTargetsIndicationApprovalStrategic role
Trastuzumab Deruxtecan (Enhertu)HER2 × Topo IHER2+/HER2-low breast, gastric, NSCLC2019-12Class-defining HER2 ADC
Datopotamab Deruxtecan (Datroway)Trop-2 × Topo IHR+/HER2− and TNBC breast cancer2024-12Trop-2 frontier vs Sacituzumab
Patritumab DeruxtecanHER3 × Topo IEGFR-mutant NSCLC (filed)PipelineHER3 first-in-class candidate
Ifinatamab DeruxtecanB7-H3 × Topo ISmall cell lung cancer (Phase 3)PipelineB7-H3 SCLC opportunity

2. Pfizer (ex-Seagen) (Tier 1 — Leader)

Primary route: MMAE microtubule ADC franchise built on Seagen’s vc-MMAE platform. Key approved products: Brentuximab Vedotin (Adcetris, 2011) for Hodgkin lymphoma. Enfortumab Vedotin (Padcev, 2019, with Astellas) for urothelial carcinoma. Tisotumab Vedotin (Tivdak, 2021, with Genmab) for cervical cancer. Inotuzumab Ozogamicin (Besponsa, 2017) for B-ALL. Differentiation: Pfizer closed the $43B Seagen acquisition in December 2023, which gave it the deepest installed MMAE pipeline in the antibody-drug conjugate competitive landscape. Trajectory: Padcev now sits at the front line of urothelial carcinoma in combination with pembrolizumab. As a result, Pfizer is leveraging Seagen’s vc-MMAE chemistry across solid-tumor expansion programs. Key risk: Microtubule payloads face ocular toxicity and competition from DXd-class agents in HER2 and Trop-2 indications.

3. AbbVie (ex-ImmunoGen) (Tier 1 — Leader)

Primary route: Maytansinoid plus auristatin ADCs anchored by ImmunoGen’s IGN linker chemistry. Key approved products: Mirvetuximab Soravtansine (Elahere, 2022) for FRα-positive ovarian cancer. Telisotuzumab Vedotin (Emrelis, 2025-05) for c-Met overexpressing NSCLC. Pivekimab Sunirine (Imitamune, 2026-05) for blastic plasmacytoid dendritic cell neoplasm and AML. Differentiation: AbbVie closed the $10.1B ImmunoGen acquisition in February 2024. The deal added the IGN PBD-class payload and sulfo-SPDB linker to the AbbVie pipeline. Trajectory: AbbVie now competes head-on with Pfizer-Seagen in the MMAE niche. Furthermore, the Pivekimab approval has revived interest in PBD chemistry for hematologic targets. Key risk: The first-generation maytansinoid ADCs (T-DM1 archetype) face DXd-class displacement; AbbVie must demonstrate IGN-class differentiation in head-to-head data.

4. Roche / Genentech (Tier 1 — Leader)

Primary route: Maytansinoid and MMAE microtubule ADCs. Key approved products: Trastuzumab Emtansine (Kadcyla, 2013) for HER2+ breast cancer. Polatuzumab Vedotin (Polivy, 2019) for diffuse large B-cell lymphoma. Differentiation: Polivy plus R-CHP became standard front-line therapy for high-risk DLBCL after the POLARIX trial. Trajectory: Kadcyla and Polivy together still drive multi-billion-dollar revenue. However, Roche has not added a new ADC franchise since 2019. Key risk: T-DM1 faces direct displacement by Trastuzumab Deruxtecan in the metastatic HER2+ setting. Therefore, Roche’s growth depends on next-generation conjugates currently in patent-stage filings.

5. Merck (MSD) (Tier 1 — Leader)

Primary route: ADC partnerships across Trop-2, HER3, and B7-H3. Key approved products: Sacituzumab Tirumotecan (Yikai-Da/Trodelvy successor, 2024-11, with Kelun-Botai) for breast and lung cancers. Pipeline: Patritumab Deruxtecan partnership with Daiichi Sankyo. Furthermore, Merck holds multiple Kelun co-development assets for ex-China rights. Differentiation: Unlike the Tier-1 owner-developers, Merck’s ADC strategy is partnership-led. As a result, the company can layer ADC franchises onto pembrolizumab combination strategies without owning conjugation chemistry. Trajectory: Merck has positioned itself to lead chemo-IO ADC combination launches by 2027. Key risk: Partnership economics reduce per-asset margin compared with owned platforms.

6. Gilead Sciences (Tier 1 — Leader)

Primary route: Trop-2 ADC franchise. Key approved product: Sacituzumab Govitecan (Trodelvy, 2020) for triple-negative breast cancer and HR+/HER2− breast cancer. Pipeline: 5 of 150 sampled 2023+ ADC patents — covering linker chemistry and next-generation Trop-2 conjugates. Differentiation: Trodelvy was the first Trop-2 ADC approved globally. As a result, Gilead holds first-mover advantage in metastatic TNBC. Trajectory: Trodelvy faces direct competition from Datopotamab Deruxtecan and Sacituzumab Tirumotecan. Therefore, Gilead is investing in next-generation Trop-2 chemistry to defend share. Key risk: Trodelvy’s neutropenia profile remains a meaningful tolerability barrier.

7. Hengrui / Kelun-Botai (Tier 2 — Challenger)

Primary route: China-originated HER2, Trop-2, B7-H3, and Nectin-4 ADCs. Key approved products: Trastuzumab Rezetecan (Hengrui, 2025-05) for HER2+ breast cancer and HER2-mutant NSCLC. Sacituzumab Tirumotecan (Kelun, partnered with Merck, 2024-11). Trastuzumab Botidotin (Kelun, 2025-10). Differentiation: Combined Hengrui plus Kelun-Botai filings represent 8 of 150 sampled 2023+ ADC patents. Together, they form the largest China-led ADC platform footprint. Trajectory: Both companies have multi-billion-dollar ex-China licensing economics with Merck and other Western partners. Key risk: Geopolitical pressure on China-to-US biotech licensing — including BIOSECURE-style legislation — could slow ex-China deal flow.


BD Deals & Strategic Moves

Business development activity has reshaped the antibody-drug conjugate competitive landscape between 2022 and 2026. The pattern is clear: Western big pharma is paying premium upfronts for de-risked Chinese ADC assets, while platform M&A consolidates conjugation chemistry under fewer owners.

2022–2026 Deal Timeline

DateDealPartiesTypeSignificance
2022-12Sacituzumab Tirumotecan ex-China licenseKelun-Botai → Merck (MSD)Out-licenseUp to $9.5B in disclosed value across multiple ADC assets; defining China-to-US ADC megadeal
2023-03Seagen acquisition announcedSeagen → PfizerAcquisition$43B all-cash; closed Dec 2023; largest oncology deal of the decade
2023-04Synaffix acquisitionSynaffix → LonzaAcquisition~$108M upfront plus milestones; consolidates GlycoConnect site-specific chemistry
2023-10Datopotamab Deruxtecan + AZ co-development expansionDaiichi Sankyo + AstraZenecaPartnership$22B-class collaboration extends DXd platform across multiple targets
2023-11ImmunoGen acquisition announcedImmunoGen → AbbVieAcquisition$10.1B; closed Feb 2024; adds IGN PBD chemistry plus Mirvetuximab Soravtansine
2023-12BNT323/DB-1303 licenseDuality Biologics → BioNTechOut-licenseHER2 ADC ex-China license; sets precedent for Duality’s Western pipeline
2024-11Sacituzumab Tirumotecan FDA approvalKelun-Botai / MerckRegulatoryFirst China-originated Trop-2 ADC approval; validates Merck-Kelun BD thesis
2024-12Datopotamab Deruxtecan FDA approvalDaiichi Sankyo / AstraZenecaRegulatoryDatroway approval extends DXd franchise into Trop-2 breast cancer
2025-05Trastuzumab Rezetecan approvalHengruiRegulatoryFirst Hengrui-originated ADC approval; HER2+ breast and HER2-mutant NSCLC
2025-05Telisotuzumab Vedotin FDA approvalAbbVieRegulatoryFirst c-Met overexpressing NSCLC ADC; orphan-style entry
2025-10Trastuzumab Botidotin approvalKelun-BotaiRegulatorySecond Kelun ADC franchise; HER2+ breast cancer
2025-10Becotatug Vedotin approvalLepu Biopharma / MiracogenRegulatoryFirst EGFR ADC approved globally; nasopharyngeal carcinoma niche
2026-05Pivekimab Sunirine approvalAbbVieRegulatoryFirst CD123 PBD-IGN ADC; blastic plasmacytoid dendritic cell neoplasm and AML

Strategic Pattern

Strategic pattern: Three deal archetypes now drive the ADC competitive landscape. First, mega-acquisitions consolidate ADC chemistry inside big pharma (Pfizer-Seagen, AbbVie-ImmunoGen, Lonza-Synaffix). Second, Chinese platform biotechs out-license late-stage assets at premium multiples (Kelun-Merck, Hengrui ex-China, Duality-BioNTech). Third, Daiichi Sankyo and AstraZeneca remain the pacesetters, expanding the DXd franchise across HER2, Trop-2, HER3, and B7-H3. As a result, the next 24 months should see continued consolidation pressure and at least 4–6 additional China-origin ADC approvals.


Unmet Needs & White Spaces

Three white spaces meet all three criteria — sparse coverage, clear technical value, and a realistic entry path for new ADC programs.

White SpaceCurrent CoverageTechnical ValueEntry Path
Bispecific and dual-payload ADCsSparse — no approved bispecific ADC; Daiichi/Hengrui/Pfizer hold patent-stage filings.High — dual targeting may overcome heterogeneous antigen expression and resistance to single-target ADCs.HER2×EGFR, HER2×CD3, Nectin-4×Trop-2 architectures with dual or tandem payloads; partnership-driven with platform biotechs.
Non-oncology ADC programs (autoimmune, infectious disease)Sparse — Cidara has 4 of 150 sampled 2023+ patents in antifungal ADC adjacent space; otherwise oncology-only.High — selective immune-cell depletion in autoimmune disease, plus pathogen-targeted ADCs for resistant infections.B-cell-depleting ADCs for refractory lupus, antifungal/antibacterial conjugates with novel payloads.
Solid-tumor ADCs beyond HER2 / Trop-2 / Nectin-4Sparse — most pipelines crowd onto the same five validated targets; broader solid-tumor antigen space remains under-explored.High — antigens such as CDH6, GPC3, CLDN18.2, MUC16, and 5T4 cover large unmet patient populations.Targeted antibody discovery paired with site-specific conjugation platforms (GeneQuantum, Synaffix, Sutro, LegoChem).

Risks and Strategic Outlook for 2026 and Beyond

Key Risks

  1. HER2 / Trop-2 commoditisation: The HER2 ADC space already counts T-DXd, T-DM1, Disitamab Vedotin, Trastuzumab Rezetecan, and Trastuzumab Botidotin. Furthermore, Trop-2 has Sacituzumab Govitecan, Datopotamab Deruxtecan, and Sacituzumab Tirumotecan. As a result, pricing pressure and label competition will intensify by 2027. Differentiation now hinges on combination data with checkpoint inhibitors and on tolerability profile.
  2. Class-level safety signals: Interstitial lung disease (ILD) for DXd-class agents and ocular toxicity for MMAE-class agents both remain unresolved. Therefore, regulators continue to require risk-mitigation strategies and post-marketing commitments. These requirements raise development cost and slow combination-trial timelines.
  3. Cross-border BD volatility: Geopolitical pressure on China-to-US biotech licensing — including BIOSECURE-style legislation — could disrupt the Merck-Kelun, BioNTech-Duality, and Hengrui ex-China deal pipeline. Programs anchored to a single ex-China license carry political risk that platform biotechs do not.
  4. Conjugation IP density: 1,293 ADC-tagged patents filed since 2023 indicate active fence-building around linker chemistry, drug-antibody ratio control, and site-specific conjugation. As a result, freedom-to-operate analyses for new entrants are increasingly non-trivial.

Strategic Outlook

For strategic planning purposes, the safest near-term bets in the antibody-drug conjugate competitive landscape are conjugation-platform plays (Synaffix/Lonza GlycoConnect, GeneQuantum iLDC, Sutro XpressCF, LegoChem). Their value compounds across multiple licensee programs. The highest-upside, highest-risk bets sit in bispecific and dual-payload ADCs and in solid-tumor antigens beyond HER2 / Trop-2 / Nectin-4. White-space opportunities also exist in non-oncology ADCs, but they require either a delivery-platform advantage or a differentiated payload class. Finally, expect continued China-origin approval acceleration in 2026–2027, particularly in HER2, Trop-2, B7-H3, and EGFR ADCs.

If you want to generate similar competitive landscape reports for other targets, drugs, or companies, AI tools like Eureka LS can significantly reduce the time and effort required, while improving consistency and depth of analysis.

Turn Complex Data into Decision-Ready Insights

Use Eureka LS to generate competitive intelligence reports across any target, drug, or company.

  • ✔ Domain-specific research Q&A
  • ✔ Patent & literature analysis (2 files per upload)
  • ✔ Lead compound analysis with SAR extraction (5 runs)
  • ✔ 2 AI-powered Pulse briefs for early signals
Try It Free →
Try Eureka LS free
Antibody drug conjugate biotech analysis competitive landscape drug discovery drug pipeline pharma market
Share. Facebook Twitter LinkedIn Email
Previous ArticleBispecific Antibody — Global Competitive Landscape Report 2026 | ASCO 2026
Next Article Small Molecule Targeted Drug — Global Competitive Landscape Report 2026 | ASCO 2026

Related Posts

How to Convert an SDF File to CSV and Keep the Structures Visible

October 23, 2026

What Is a Linker in a Drug Molecule?

October 23, 2026

What Is Canonical SMILES?

October 23, 2026

Extracting Compounds from Molecular Glue Degrader Patents

October 23, 2026

Extracting Compounds from BTK Inhibitor Patents

October 23, 2026

Why Chemical Patents Keep Their Structures in Images

October 23, 2026

Comments are closed.

Patsnap Eureka Life Sciences

Get free access today!

Eureka LS helps you rank optimal molecules (PCC), analyze complex modalities (like ADC & CAR-T), and conduct traceable due diligence, powered by comprehensive global patent and bio-sequence data.

⚡️ Get started →
Table of Contents
  • Executive Summary
  • Arena Overview
  • Route Differentiation Analysis
  • Top Player Deep Dives
  • BD Deals & Strategic Moves
  • Unmet Needs & White Spaces
  • Risks and Strategic Outlook for 2026 and Beyond
About Us
About Us

Eureka harnesses unparalleled innovation data and effortlessly delivers breakthrough ideas for your toughest technical challenges. Eliminate complexity, achieve more.

Facebook YouTube LinkedIn
Latest Hotspot

Elementor #38874

August 7, 2026

Sheet-Metal Fastening: Pick the Process Before Cost and Reliability Slip

July 31, 2026

Learn Cost Reduction from Musk: The “Idiot Index”

July 31, 2026
tech newsletter

35 Breakthroughs in Magnetic Resonance Imaging – Product Components

July 1, 2024

27 Breakthroughs in Magnetic Resonance Imaging – Categories

July 1, 2024

40+ Breakthroughs in Magnetic Resonance Imaging – Typical Technologies

July 1, 2024
© 2026 Patsnap Eureka. Powered by Patsnap Eureka.

Type above and press Enter to search. Press Esc to cancel.